BriaCell subsidiary BriaPro completes sCD80 license acquisition

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/27/2026

1. ORCL
2. SPY
3. ANT
4. FFAI
5. FFR
6. LLY
7. TSLA
8. META
9. FICO
10. CART

Go back to BriaCell subsidiary BriaPro completes sCD80 license acquisition

BriaCell and BriaPro Announce Closing of Asset Purchase Transaction for Exclusive Soluble CD80 License

March 31, 2026 4:05 PM EDT

PHILADELPHIA and VANCOUVER, British Columbia, March 31, 2026 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW, BCTXZ, BCTXL) (TSX: BCT) (BriaCell), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, and its majority-owned subsidiary, BriaPro Therapeutics Corp. (BriaPro), today announced the completion of the previously announced asset purchase transaction (the Transaction) pursuant to a definitive purchase agreement dated February 4, 2026 (the Purchase Agreement), under which BriaPro acquired BriaCells exclusive license to develop and commercialize Soluble CD80 (sCD80) as a biologic agent for the... More